Visual abstract | Efficacy of guselkumab in treating regional psoriasis and psoriatic arthritis: post-hoc analyses of VOYAGE 1 and 2

The Psoriasis and Psoriatic Arthritis Hub is pleased to present a visual abstract summarizing post-hoc analyses of the VOYAGE 1 (NCT02207231) and VOYAGE 2 (NCT02207244) trials assessing the efficacy of guselkumab in the treatment of regional psoriasis and psoriatic arthritis (PsA).

PsA is a chronic inflammatory condition with skin and musculoskeletal involvement. Patients with PsA and nail psoriasis have a poor quality of life, experiencing higher disease activity that makes treatment challenging. Guselkumab is an inhibitor of the p19 subunit of interleukin-23, approved for the treatment of moderate-to-severe psoriasis and active PsA in adults; guselkumab has demonstrated efficacy across multiple PsA domains in the DISCOVER-1 and DISCOVER-2 trials. The post-hoc analyses by Orbai et al.¹ demonstrated that guselkumab was effective in treating psoriasis of nails, scalp, palms, and/or soles, and improved quality of life in patients with psoriasis and PsA.